Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Tecfidera

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tecfidera was produced by Biogen Idec.

FDA approves Biogen Idec's long-acting MS therapy

FDA approves Biogen Idec's long-acting MS therapy Plegridy is Biogen Idec's fifth MS treatment to reach the market joining Avonex, Tysabri (natalizumab), fast-growing oral therapy Tecfidera (dimethyl fumarate) and Fampyra (fampridine). ... Plegridy is not expected to reach the heights of Tecfidera -

Rebif hit again as competition bites

Rebif hit again as competition bites Biogen Idec's Tecfidera (dimethyl glutamate) and Novartis' Gilenya (fingolimod).

MS market set to grow 4% annually

Other key findings of the report are that Biogen's oral MS therapy Tecfidera will dominate the US market by 2015 “supported by gradually declining reliance on the platform injectable therapies”.

Plegridy approval underlines Biogen Idec's dominance in MS

Plegridy approval underlines Biogen Idec's dominance in MS And Tecfidera boosts pharma company’s second quarter financial results. Biogen Idec added a fifth product to its multiple sclerosis (MS) franchise last week after the European Commission approved long-acting ... Tecfidera boosts financial performance.

Novartis' vaccine sales decline ahead of GSK transfer

Novartis' vaccine sales decline ahead of GSK transfer Particularly in Europe, Gilenya has held up well in the face of competition from Biogen Idec's recently-launched rival Tecfidera (dimethyl fumarate), said Jimenez, with sales up 29 per cent

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics